Company Overview

Sol-Gel Technologies Ltd. is a dermatology-focused pharmaceutical company that develops and commercializes topical drug products based on its proprietary sol-gel delivery technology. The company operates within the dermatology and specialty pharmaceuticals industry, with a focus on improving the efficacy, tolerability, and stability of active pharmaceutical ingredients for skin conditions. Sol-Gel’s core strategy centers on developing prescription dermatology therapies and partnering with larger pharmaceutical companies for commercialization.

The company’s primary revenue drivers are royalty and milestone payments derived from licensed products, most notably EPSOLAY® and TWYNEO®, which are approved by the U.S. Food and Drug Administration for the treatment of rosacea and acne, respectively. Sol-Gel targets dermatologists and dermatology-focused healthcare providers, primarily in the U.S. market. Founded in 1997, the company has evolved from a technology-focused R&D entity into a clinical-stage and commercial-stage pharmaceutical company with FDA-approved products and established licensing partnerships.

Business Operations

Sol-Gel operates primarily through a single reporting segment focused on dermatological therapeutics, encompassing research and development, clinical trials, regulatory activities, and lifecycle management of dermatology drug candidates. The company does not maintain large-scale commercial sales operations; instead, it generates revenue through licensing agreements, under which partners are responsible for manufacturing, marketing, and distribution.

The company’s key assets include its proprietary sol-gel technology platform, which enables controlled release and improved skin penetration of active ingredients. Sol-Gel conducts most R&D activities in-house while leveraging third-party manufacturers and clinical research organizations. Commercial activities for approved products are conducted through licensing partners. The company has entered into significant licensing arrangements with Galderma, which commercializes EPSOLAY® and TWYNEO® in the United States. No material joint ventures have been publicly disclosed beyond these licensing relationships.

Strategic Position & Investments

Sol-Gel’s strategic direction emphasizes dermatology-focused innovation, lifecycle expansion of approved products, and development of new topical therapies using its proprietary delivery platform. Growth initiatives center on advancing earlier-stage dermatology candidates through clinical development while maximizing the commercial potential of already approved products through geographic expansion and indication extensions by partners.

The company’s most significant strategic transactions have been out-licensing agreements rather than acquisitions. These agreements provide upfront payments, regulatory and sales-based milestones, and ongoing royalties, allowing Sol-Gel to limit commercialization risk and capital requirements. Sol-Gel continues to invest in emerging dermatological indications where topical therapies offer clinical or safety advantages. No material acquisitions have been disclosed in public filings; data on additional portfolio investments beyond core dermatology programs is inconclusive based on available public sources.

Geographic Footprint

Sol-Gel Technologies is headquartered in Israel, with its principal executive offices and R&D operations located in Ness Ziona. The company’s operational footprint is primarily concentrated in Israel, where research, clinical strategy, and corporate management functions are based.

Commercial exposure is largely international through licensing partners, with the United States representing the most significant market due to FDA approvals and active product commercialization. Through its partners, Sol-Gel’s products also have potential reach into Europe and other international markets, although commercial rollout and market penetration outside the U.S. depend on partner strategies and regulatory approvals. The company itself does not maintain a direct sales presence across continents.

Leadership & Governance

Sol-Gel is led by executives with experience in pharmaceuticals, dermatology, and corporate management. The leadership team emphasizes disciplined R&D execution, regulatory compliance, and value creation through strategic partnerships rather than vertical integration.

Key executives include:

• Alon Seri-Levy – Chief Executive Officer
• Ronen Faier – Chairman of the Board

Public disclosures confirm the roles of the CEO and Chairman; however, information regarding additional named executive officers varies across sources. Data inconclusive based on available public sources for a complete and consistently verified list of other senior executives beyond those listed above.